A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions

Background Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. Objective The present review aims to systematically...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PharmacoEconomics Ročník 34; číslo 8; s. 771 - 793
Hlavní autoři: Plumpton, Catrin O., Roberts, Daniel, Pirmohamed, Munir, Hughes, Dyfrig A.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Cham Springer International Publishing 01.08.2016
Springer
Springer Nature B.V
Témata:
Adverse and side effects
Cost-Benefit Analysis
Drug-Related Side Effects and Adverse Reactions - economics
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - prevention & control
Drugs
Economic aspects
Evaluation
Genotype
Health Administration
Health Economics
Humans
Incidence
Medicine
Medicine & Public Health
Methods
Pharmacoeconomics and Health Outcomes
Pharmacogenetics
Pharmacogenetics - economics
Pharmacogenetics - methods
Pharmacogenomic Testing - economics
Pharmacogenomic Testing - methods
Public Health
Quality of Life Research
Side effects
Systematic Review
United Kingdom
Prasugrel
Clopidogrel
Economic Evaluation
Carbamazepine
Abacavir
ISSN:1170-7690, 1179-2027
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Background Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. Objective The present review aims to systematically review published economic evaluations of pharmacogenetic tests that aim to prevent or reduce the incidence of ADRs. Methods We conducted a systematic literature review of economic evaluations of pharmacogenetic tests aimed to reduce the incidence of adverse drug reactions. Literature was searched using Embase, MEDLINE and the NHS Economic Evaluation Database with search terms relating to pharmacogenetic testing, adverse drug reactions, economic evaluations and pharmaceuticals. Titles were screened independently by two reviewers. Articles deemed to meet the inclusion criteria were screened independently on abstract, and full texts reviewed. Results We identified 852 articles, of which 47 met the inclusion criteria. There was evidence supporting the cost effectiveness of testing for HLA - B*57:01 (prior to abacavir), HLA - B*15:02 and HLA - A*31:01 (prior to carbamazepine), HLA - B*58:01 (prior to allopurinol) and CYP2C19 (prior to clopidogrel treatment). Economic evidence was inconclusive with respect to TPMT (prior to 6-mercaptoputine, azathioprine and cisplatin therapy), CYP2C9 and VKORC1 (to inform genotype-guided dosing of coumarin derivatives), MTHFR (prior to methotrexate treatment) and factor V Leiden testing (prior to oral contraception). Testing for A1555G is not cost effective before prescribing aminoglycosides. Conclusions Our systematic review identified robust evidence of the cost effectiveness of genotyping prior to treatment with a number of common drugs. However, further analyses and (or) availability of robust clinical evidence is necessary to make recommendations for others.
AbstractList BACKGROUNDPharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness.OBJECTIVEThe present review aims to systematically review published economic evaluations of pharmacogenetic tests that aim to prevent or reduce the incidence of ADRs.METHODSWe conducted a systematic literature review of economic evaluations of pharmacogenetic tests aimed to reduce the incidence of adverse drug reactions. Literature was searched using Embase, MEDLINE and the NHS Economic Evaluation Database with search terms relating to pharmacogenetic testing, adverse drug reactions, economic evaluations and pharmaceuticals. Titles were screened independently by two reviewers. Articles deemed to meet the inclusion criteria were screened independently on abstract, and full texts reviewed.RESULTSWe identified 852 articles, of which 47 met the inclusion criteria. There was evidence supporting the cost effectiveness of testing for HLA-B*57:01 (prior to abacavir), HLA-B*15:02 and HLA-A*31:01 (prior to carbamazepine), HLA-B*58:01 (prior to allopurinol) and CYP2C19 (prior to clopidogrel treatment). Economic evidence was inconclusive with respect to TPMT (prior to 6-mercaptoputine, azathioprine and cisplatin therapy), CYP2C9 and VKORC1 (to inform genotype-guided dosing of coumarin derivatives), MTHFR (prior to methotrexate treatment) and factor V Leiden testing (prior to oral contraception). Testing for A1555G is not cost effective before prescribing aminoglycosides.CONCLUSIONSOur systematic review identified robust evidence of the cost effectiveness of genotyping prior to treatment with a number of common drugs. However, further analyses and (or) availability of robust clinical evidence is necessary to make recommendations for others.
Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. The present review aims to systematically review published economic evaluations of pharmacogenetic tests that aim to prevent or reduce the incidence of ADRs. We conducted a systematic literature review of economic evaluations of pharmacogenetic tests aimed to reduce the incidence of adverse drug reactions. Literature was searched using Embase, MEDLINE and the NHS Economic Evaluation Database with search terms relating to pharmacogenetic testing, adverse drug reactions, economic evaluations and pharmaceuticals. Titles were screened independently by two reviewers. Articles deemed to meet the inclusion criteria were screened independently on abstract, and full texts reviewed. We identified 852 articles, of which 47 met the inclusion criteria. There was evidence supporting the cost effectiveness of testing for HLA-B*57:01 (prior to abacavir), HLA-B*15:02 and HLA-A*31:01 (prior to carbamazepine), HLA-B*58:01 (prior to allopurinol) and CYP2C19 (prior to clopidogrel treatment). Economic evidence was inconclusive with respect to TPMT (prior to 6-mercaptoputine, azathioprine and cisplatin therapy), CYP2C9 and VKORC1 (to inform genotype-guided dosing of coumarin derivatives), MTHFR (prior to methotrexate treatment) and factor V Leiden testing (prior to oral contraception). Testing for A1555G is not cost effective before prescribing aminoglycosides. Our systematic review identified robust evidence of the cost effectiveness of genotyping prior to treatment with a number of common drugs. However, further analyses and (or) availability of robust clinical evidence is necessary to make recommendations for others.
Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. The present review aims to systematically review published economic evaluations of pharmacogenetic tests that aim to prevent or reduce the incidence of ADRs. We conducted a systematic literature review of economic evaluations of pharmacogenetic tests aimed to reduce the incidence of adverse drug reactions. Literature was searched using Embase, MEDLINE and the NHS Economic Evaluation Database with search terms relating to pharmacogenetic testing, adverse drug reactions, economic evaluations and pharmaceuticals. Titles were screened independently by two reviewers. Articles deemed to meet the inclusion criteria were screened independently on abstract, and full texts reviewed. We identified 852 articles, of which 47 met the inclusion criteria. There was evidence supporting the cost effectiveness of testing for HLA-B*57:01 (prior to abacavir), HLA-B*15:02 and HLA-A*31:01 (prior to carbamazepine), HLA-B*58:01 (prior to allopurinol) and CYP2C19 (prior to clopidogrel treatment). Economic evidence was inconclusive with respect to TPMT (prior to 6-mercaptoputine, azathioprine and cisplatin therapy), CYP2C9 and VKORC1 (to inform genotype-guided dosing of coumarin derivatives), MTHFR (prior to methotrexate treatment) and factor V Leiden testing (prior to oral contraception). Testing for A1555G is not cost effective before prescribing aminoglycosides. Our systematic review identified robust evidence of the cost effectiveness of genotyping prior to treatment with a number of common drugs. However, further analyses and (or) availability of robust clinical evidence is necessary to make recommendations for others.
Background Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. Objective The present review aims to systematically review published economic evaluations of pharmacogenetic tests that aim to prevent or reduce the incidence of ADRs. Methods We conducted a systematic literature review of economic evaluations of pharmacogenetic tests aimed to reduce the incidence of adverse drug reactions. Literature was searched using Embase, MEDLINE and the NHS Economic Evaluation Database with search terms relating to pharmacogenetic testing, adverse drug reactions, economic evaluations and pharmaceuticals. Titles were screened independently by two reviewers. Articles deemed to meet the inclusion criteria were screened independently on abstract, and full texts reviewed. Results We identified 852 articles, of which 47 met the inclusion criteria. There was evidence supporting the cost effectiveness of testing for HLA-B*57:01 (prior to abacavir), HLA-B*15:02 and HLA-A*31:01 (prior to carbamazepine), HLA-B*58:01 (prior to allopurinol) and CYP2C19 (prior to clopidogrel treatment). Economic evidence was inconclusive with respect to TPMT (prior to 6-mercaptoputine, azathioprine and cisplatin therapy), CYP2C9 and VKORC1 (to inform genotype-guided dosing of coumarin derivatives), MTHFR (prior to methotrexate treatment) and factor V Leiden testing (prior to oral contraception). Testing for A1555G is not cost effective before prescribing aminoglycosides. Conclusions Our systematic review identified robust evidence of the cost effectiveness of genotyping prior to treatment with a number of common drugs. However, further analyses and (or) availability of robust clinical evidence is necessary to make recommendations for others.
Background Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. Objective The present review aims to systematically review published economic evaluations of pharmacogenetic tests that aim to prevent or reduce the incidence of ADRs. Methods We conducted a systematic literature review of economic evaluations of pharmacogenetic tests aimed to reduce the incidence of adverse drug reactions. Literature was searched using Embase, MEDLINE and the NHS Economic Evaluation Database with search terms relating to pharmacogenetic testing, adverse drug reactions, economic evaluations and pharmaceuticals. Titles were screened independently by two reviewers. Articles deemed to meet the inclusion criteria were screened independently on abstract, and full texts reviewed. Results We identified 852 articles, of which 47 met the inclusion criteria. There was evidence supporting the cost effectiveness of testing for HLA - B*57:01 (prior to abacavir), HLA - B*15:02 and HLA - A*31:01 (prior to carbamazepine), HLA - B*58:01 (prior to allopurinol) and CYP2C19 (prior to clopidogrel treatment). Economic evidence was inconclusive with respect to TPMT (prior to 6-mercaptoputine, azathioprine and cisplatin therapy), CYP2C9 and VKORC1 (to inform genotype-guided dosing of coumarin derivatives), MTHFR (prior to methotrexate treatment) and factor V Leiden testing (prior to oral contraception). Testing for A1555G is not cost effective before prescribing aminoglycosides. Conclusions Our systematic review identified robust evidence of the cost effectiveness of genotyping prior to treatment with a number of common drugs. However, further analyses and (or) availability of robust clinical evidence is necessary to make recommendations for others.
Audience Academic
Author Pirmohamed, Munir
Roberts, Daniel
Hughes, Dyfrig A.
Plumpton, Catrin O.
Author_xml – sequence: 1
  givenname: Catrin O.
  surname: Plumpton
  fullname: Plumpton, Catrin O.
  organization: Centre for Health Economics and Medicines Evaluation, Bangor University
– sequence: 2
  givenname: Daniel
  surname: Roberts
  fullname: Roberts, Daniel
  organization: Centre for Health Economics and Medicines Evaluation, Bangor University
– sequence: 3
  givenname: Munir
  surname: Pirmohamed
  fullname: Pirmohamed, Munir
  organization: Department of Molecular and Clinical Pharmacology, University of Liverpool
– sequence: 4
  givenname: Dyfrig A.
  surname: Hughes
  fullname: Hughes, Dyfrig A.
  email: d.a.hughes@bangor.ac.uk
  organization: Centre for Health Economics and Medicines Evaluation, Bangor University, Department of Molecular and Clinical Pharmacology, University of Liverpool
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26984520$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhiNURD_gB3BBkbhwSRl_xI6Pq3ZpkSpRQTlbXmccUiV2sZNF_fc4u61UKkA-2Bo_7-vxzBwXBz54LIq3BE4JgPyYOFDJKiCiAqZkpV4UR4RIVdEcP9idoZJCwWFxnNItAAgm6avikArV8JrCURFW5bf7NOFopt6WX3Hb468yuHJtgw9jDq23ZpjzZfBpiV__MHE0NnTocVHcYJp635UuxPI64hb9gi7kqt1iTFiex7nLxsbuPF4XL50ZEr552E-K75_WN2eX1dWXi89nq6vKcqaminFoLHMMXO2sY41qrWJScGs3pt5wI4AbiiZ_yCEHBGok39RoBCMCbFuzk-LD3vcuhp9zTlKPfbI4DMZjmJMmDRBOpWxIRt8_Q2_DHH3OLlOUEBBcPaE6M6DuvQtTNHYx1StJeK0aUUOmTv9C5dViLmbunutz_A_Bu4fH582Irb6L_WjivX7sUAbkHrAxpBTRadtPu35k537QBPQyC3o_CzrPgl5mQausJM-Uj-b_09C9JmXWdxif1OKfot8xOMP8
CitedBy_id crossref_primary_10_3390_jcm9061801
crossref_primary_10_1007_s00500_022_06951_x
crossref_primary_10_2217_pgs_2020_0130
crossref_primary_10_3389_fphar_2024_1399172
crossref_primary_10_1038_s41397_018_0039_z
crossref_primary_10_2217_pgs_2020_0096
crossref_primary_10_2217_pgs_2017_0090
crossref_primary_10_6061_clinics_2018_e565s
crossref_primary_10_2217_pgs_2022_0148
crossref_primary_10_1136_jnnp_2023_331419
crossref_primary_10_2217_pgs_2018_0097
crossref_primary_10_1080_17425255_2017_1233965
crossref_primary_10_1155_2017_6198530
crossref_primary_10_1208_s12248_017_0161_x
crossref_primary_10_1016_j_iac_2022_01_006
crossref_primary_10_1016_j_knosys_2020_105978
crossref_primary_10_3390_ijms23020628
crossref_primary_10_1111_bjd_15498
crossref_primary_10_1007_s11825_017_0146_2
crossref_primary_10_1155_2023_6105320
crossref_primary_10_1002_cpt_1030
crossref_primary_10_1038_s41397_019_0083_3
crossref_primary_10_1016_j_farma_2022_12_017
crossref_primary_10_1038_tpj_2016_41
crossref_primary_10_2217_pgs_2020_0168
crossref_primary_10_3390_ijms222413302
crossref_primary_10_1016_j_farma_2023_03_004
crossref_primary_10_2217_pgs_2019_0134
crossref_primary_10_1002_cpt_1312
crossref_primary_10_1146_annurev_pharmtox_052120_014115
crossref_primary_10_3390_jcm10225317
crossref_primary_10_3390_genes11111337
crossref_primary_10_1038_s41397_018_0047_z
crossref_primary_10_1071_PY18047
crossref_primary_10_1136_bmjopen_2025_104311
crossref_primary_10_3390_genes10040261
crossref_primary_10_1007_s40258_017_0318_x
crossref_primary_10_1007_s40291_017_0257_0
crossref_primary_10_1097_FPC_0000000000000487
crossref_primary_10_3390_microorganisms12020242
crossref_primary_10_1007_s00038_019_01298_x
crossref_primary_10_1016_j_jval_2022_01_006
crossref_primary_10_1016_j_tips_2016_11_003
crossref_primary_10_2217_pgs_2017_0303
crossref_primary_10_1186_s12913_021_07260_z
crossref_primary_10_2217_pgs_2017_0063
crossref_primary_10_1016_j_asoc_2021_107324
crossref_primary_10_3389_fphar_2023_1247088
crossref_primary_10_3390_jpm8030022
crossref_primary_10_1016_j_heliyon_2020_e03990
crossref_primary_10_1002_cpt_683
crossref_primary_10_1007_s11095_018_2472_8
crossref_primary_10_1080_14740338_2023_2181337
crossref_primary_10_3389_fpsyt_2019_00690
crossref_primary_10_1177_1074248420902298
crossref_primary_10_3390_pharmaceutics12121240
crossref_primary_10_1080_03036758_2024_2406824
crossref_primary_10_1186_s12913_021_07025_8
crossref_primary_10_2217_pgs_2020_0029
crossref_primary_10_1111_bjd_15832
crossref_primary_10_1016_j_artmed_2025_103275
crossref_primary_10_1016_j_neuroscience_2019_01_024
crossref_primary_10_2217_pgs_2017_0076
crossref_primary_10_2217_pgs_2020_0187
crossref_primary_10_1016_j_radonc_2017_08_034
crossref_primary_10_1136_bmjopen_2019_032624
crossref_primary_10_2217_pgs_2020_0181
crossref_primary_10_2147_PGPM_S320816
crossref_primary_10_1038_s41397_025_00379_w
crossref_primary_10_1111_joim_13772
crossref_primary_10_1007_s11096_017_0451_5
crossref_primary_10_1007_s13167_024_00353_9
crossref_primary_10_1186_s12859_023_05212_4
crossref_primary_10_1002_cpt_951
crossref_primary_10_1080_14737167_2017_1385395
crossref_primary_10_1007_s40278_016_16045_3
crossref_primary_10_1038_s41576_022_00572_8
crossref_primary_10_1111_bph_17414
crossref_primary_10_1016_j_radonc_2019_09_020
crossref_primary_10_1515_dmpt_2016_0025
crossref_primary_10_1007_s40495_022_00310_y
crossref_primary_10_3389_fmed_2022_809393
crossref_primary_10_1371_journal_pone_0213929
crossref_primary_10_1089_ipm_09_01_16
crossref_primary_10_3390_jpm9030042
crossref_primary_10_1080_20786190_2019_1610233
crossref_primary_10_1136_bmjopen_2020_037443
crossref_primary_10_1002_jac5_1062
crossref_primary_10_3389_fphar_2022_918493
crossref_primary_10_1109_JBHI_2023_3343911
crossref_primary_10_1002_cpt_2079
crossref_primary_10_1177_1533033819873924
crossref_primary_10_1111_ijcp_13088
Cites_doi 10.1136/bmj.b2535
10.2165/00019053-200422080-00001
10.1002/cncr.24428
10.1097/FPC.0000000000000107
10.2217/pgs.13.164
10.1016/S0140-6736(12)60161-5
10.1186/2047-783X-15-4-145
10.2217/14622416.9.5.539
10.1038/clpt.2009.104
10.1111/j.1572-0241.2005.41900.x
10.1056/NEJMoa0706135
10.1111/jth.12059
10.1136/bmj.329.7456.15
10.1038/nrd3921
10.1016/j.pnpbp.2011.08.013
10.2165/11318240-000000000-00000
10.2217/pgs.13.74
10.2165/11535540-000000000-00000
10.1097/GIM.0b013e318156dd07
10.1371/journal.pone.0039640
10.1056/NEJMoa1310669
10.1146/annurev-genom-090413-025419
10.1002/pbc.22936
10.1371/journal.pone.0094294
10.1016/j.clpt.2006.03.008
10.1016/j.eimc.2009.09.010
10.1093/rheumatology/keh001
10.1038/clpt.2013.190
10.2217/pgs.10.45
10.1111/j.1365-2036.2004.02124.x
10.1016/j.tips.2004.02.007
10.1007/s12016-014-8418-y
10.2217/pgs.10.74
10.1161/CIRCOUTCOMES.108.808592
10.1097/QAD.0b013e3283103ce6
10.2165/11595080-000000000-00000
10.2165/11537410-000000000-00000
10.1017/S0266462308080392
10.1155/2005/470863
10.2217/pgs.11.32
10.2217/pgs.14.52
10.1371/journal.pone.0004439
10.1002/j.1875-9114.2012.01048
10.1001/jama.279.15.1200
10.1038/tpj.2011.15
10.2217/14622416.7.5.783
10.1067/mjd.2000.103980
10.1016/S0015-0282(99)00318-0
10.1212/WNL.0b013e31826aac73
10.1111/epi.12937
10.2165/00019053-200624080-00004
10.1016/j.jval.2013.10.007
10.1007/s11096-013-9777-9
10.1517/14622416.5.8.1139
10.1016/j.jval.2013.02.002
10.1097/00008571-200406000-00002
10.2217/pgs.10.145
10.7326/0003-4819-150-2-200901200-00005
10.1007/s00408-009-9217-8
10.2217/17410541.5.3.279
10.18433/J3WK5S
10.1002/acr.22409
10.1111/epi.12325
10.1056/NEJMoa1311386
10.1016/j.amjopharm.2009.07.002
10.1160/TH08-03-0149
ContentType Journal Article
Copyright Springer International Publishing Switzerland 2016
COPYRIGHT 2016 Springer
Copyright Springer Science & Business Media Aug 2016
Copyright_xml – notice: Springer International Publishing Switzerland 2016
– notice: COPYRIGHT 2016 Springer
– notice: Copyright Springer Science & Business Media Aug 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
4T-
7WY
7WZ
7X7
7XB
87Z
88C
88E
88G
8C1
8FI
8FJ
8FK
8FL
ABUWG
AFKRA
AZQEC
BENPR
BEZIV
CCPQU
DWQXO
FRNLG
FYUFA
F~G
GHDGH
GNUQQ
K60
K6~
K9.
L.-
M0C
M0S
M0T
M1P
M2M
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQBIZ
PQBZA
PQEST
PQQKQ
PQUKI
PSYQQ
Q9U
7U8
7X8
C1K
JXQ
DOI 10.1007/s40273-016-0397-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Docstoc
ABI/INFORM Complete
ABI/INFORM Global (PDF only)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ABI/INFORM Global (Alumni Edition)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ABI/INFORM Collection (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Business Premium Collection
ProQuest One
ProQuest Central
Business Premium Collection (Alumni)
Health Research Premium Collection
ABI/INFORM Global (Corporate)
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Business Collection (Alumni Edition)
ProQuest Business Collection
ProQuest Health & Medical Complete (Alumni)
ABI/INFORM Professional Advanced
ABI/INFORM Global
Health & Medical Collection (Alumni Edition)
Healthcare Administration Database
PML(ProQuest Medical Library)
Psychology Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Business
ProQuest One Business (Alumni)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest One Psychology
ProQuest Central Basic
TOXLINE
MEDLINE - Academic
Environmental Sciences and Pollution Management
Toxline
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ABI/INFORM Global (Corporate)
ProQuest Business Collection (Alumni Edition)
ProQuest One Business
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ABI/INFORM Complete
ProQuest Central
ABI/INFORM Professional Advanced
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ABI/INFORM Complete (Alumni Edition)
Business Premium Collection
ABI/INFORM Global
ProQuest Public Health
ABI/INFORM Global (Alumni Edition)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Health Management
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
ProQuest Business Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
Docstoc
ProQuest Health Management (Alumni Edition)
ProQuest One Business (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
Business Premium Collection (Alumni)
TOXLINE
MEDLINE - Academic
Environmental Sciences and Pollution Management
DatabaseTitleList TOXLINE
ABI/INFORM Global (Corporate)

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: M0T
  name: Healthcare Administration Database
  url: https://search.proquest.com/healthmanagement
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Economics
Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1179-2027
EndPage 793
ExternalDocumentID 4187481201
A714598650
26984520
10_1007_s40273_016_0397_9
Genre Systematic Review
Journal Article
Feature
GeographicLocations United Kingdom
GeographicLocations_xml – name: United Kingdom
GrantInformation_xml – fundername: National Institute for Health Research
  grantid: II-LB-0313-20008; II-LB-0313-20008; II-LB-0313-20008
  funderid: http://dx.doi.org/10.13039/501100000272
– fundername: Department of Health
  grantid: II-LB-0313-20008
– fundername: Medical Research Council
  grantid: MR/L006758/1
GroupedDBID ---
-5G
-BR
-EM
0R~
0VX
123
199
29O
36B
3V.
4.4
406
53G
6I2
7WY
7X7
88E
8C1
8FI
8FJ
8FL
8R4
8R5
8V8
95.
AAAUJ
AACDK
AADNT
AAIAL
AAIKX
AAJKR
AAKAS
AANZL
AARHV
AASML
AATNV
AAWTL
AAYOK
AAYQN
AAYTO
ABAKF
ABDZT
ABFTV
ABIVO
ABJNI
ABJOX
ABKCH
ABKMS
ABKTR
ABOCM
ABPLI
ABTKH
ABTMW
ABUWG
ABWHX
ABXPI
ACAOD
ACCOQ
ACCUX
ACDTI
ACGFO
ACGFS
ACHQT
ACMJI
ACMLO
ACOKC
ACPIV
ACREN
ACZOJ
ADBBV
ADFRT
ADFZG
ADHHG
ADQRH
ADRFC
ADURQ
ADYOE
ADZCM
ADZKW
AEBTG
AEFQL
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AEVLU
AEXYK
AEYRQ
AFALF
AFBBN
AFKRA
AFWTZ
AFZKB
AGAYW
AGDGC
AGQEE
AGQMX
AGRTI
AHMBA
AHSBF
AIAKS
AIGIU
AILAN
AIZAD
AJRNO
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AQUVI
ASPBG
AVWKF
AWSVR
AXYYD
AZFZN
AZQEC
A~4
BENPR
BEZIV
BGNMA
BPHCQ
BVXVI
BYPQX
CAG
CCPQU
COF
CS3
DCUDU
DNIVK
DPUIP
DU5
DWQXO
EBLON
EBR
EBS
EBU
EJD
EMOBN
ESX
F5P
FERAY
FIGPU
FLLZZ
FNLPD
FRNLG
FSGXE
FYUFA
GNUQQ
GROUPED_ABI_INFORM_RESEARCH
HG6
HMCUK
IAO
IBB
IEA
IHR
ITC
IWAJR
J-C
J5H
JZLTJ
K1G
K60
K6~
LGEZI
LLZTM
LOTEE
M0C
M0T
M1P
M2M
M4Y
NADUK
NQJWS
NU0
NXXTH
OAC
OPC
OVD
P2P
PQBIZ
PQBZA
PQQKQ
PROAC
PSQYO
PSYQQ
Q2X
RIG
ROL
RSV
RZALA
SISQX
SJYHP
SNPRN
SNX
SOHCF
SOJ
SPKJE
SRMVM
SSLCW
TEORI
TSG
U9L
UAX
UG4
UKHRP
UTJUX
VDBLX
VFIZW
W48
WAF
YFH
YQY
Z0Y
Z7U
ZMTXR
~JE
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
AEZWR
AFDZB
AFFHD
AFHIU
AFOHR
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
4T-
7XB
8FK
K9.
L.-
PKEHL
PQEST
PQUKI
Q9U
7U8
7X8
C1K
JXQ
PUEGO
ID FETCH-LOGICAL-c439t-3408c3f30f5fcf389dc93764ccba5b4a604a2ea006fe40e02a74b5ea63160cd53
IEDL.DBID M0C
ISICitedReferencesCount 108
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000379175100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1170-7690
IngestDate Fri Sep 05 12:28:59 EDT 2025
Fri Nov 07 23:38:24 EST 2025
Sat Nov 29 13:25:33 EST 2025
Sat Nov 29 09:50:21 EST 2025
Mon Jul 21 06:07:41 EDT 2025
Sat Nov 29 02:10:21 EST 2025
Tue Nov 18 22:22:54 EST 2025
Fri Feb 21 02:30:25 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Prasugrel
Clopidogrel
Economic Evaluation
Carbamazepine
Abacavir
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c439t-3408c3f30f5fcf389dc93764ccba5b4a604a2ea006fe40e02a74b5ea63160cd53
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-2
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Undefined-4
PMID 26984520
PQID 1821106491
PQPubID 43702
PageCount 23
ParticipantIDs proquest_miscellaneous_1801427781
proquest_journals_1821106491
gale_infotracmisc_A714598650
gale_infotracacademiconefile_A714598650
pubmed_primary_26984520
crossref_citationtrail_10_1007_s40273_016_0397_9
crossref_primary_10_1007_s40273_016_0397_9
springer_journals_10_1007_s40273_016_0397_9
PublicationCentury 2000
PublicationDate 20160800
2016-8-00
2016-08-00
20160801
PublicationDateYYYYMMDD 2016-08-01
PublicationDate_xml – month: 8
  year: 2016
  text: 20160800
PublicationDecade 2010
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: New Zealand
– name: Auckland
PublicationTitle PharmacoEconomics
PublicationTitleAbbrev PharmacoEconomics
PublicationTitleAlternate Pharmacoeconomics
PublicationYear 2016
Publisher Springer International Publishing
Springer
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer
– name: Springer Nature B.V
References Meckley, Gudgeon, Anderson, Williams, Veenstra (CR52) 2010; 28
Thompson, Newman, Elliott, Roberts, Tricker, Payne (CR32) 2014; 17
Patrick, Avorn, Choudhry (CR46) 2009; 2
Verhoef, Redekop, Veenstra, Thariani, Beltman, van Schie, de Boer (CR54) 2013; 14
Yip, Alfirevic, Pirmohamed (CR7) 2015; 48
Dong, Sung, Finkelstein (CR37) 2012; 79
Rattanavipapong, Koopitakkajorn, Praditsitthikorn, Mahasirimongkol, Teerawattananon (CR38) 2013; 54
Dionne, Mitton, Rassekh, Brooks, Ross, Hayden (CR60) 2012; 12
Lala, Berger, Sharma, Hochman, Braithwaite, Ladapo (CR55) 2013; 11
Kim, Jun, El-Sohemy, Bae (CR61) 2006; 33
Phillips, van Bebber (CR13) 2004; 5
Hagaman, Kinder, Eckman (CR26) 2010; 188
Kapoor, Martinez-Vega, Dong, Tan, Leo, Lee (CR23) 2015; 25
You, Chan, Wong, Cheng (CR53) 2004; 92
Pirmohamed, Hughes (CR12) 2013; 12
Calatravaa, de la Calle-Martín, Iribarren-Loyartec, Rivero-Románd, García-Bujalancee, Pérez-Escolanoe, Brosa-Riestra (CR22) 2010; 28
McWilliam, Lutter, Nardinelli (CR49) 2008; 5
Tiamkao, Jitpimolmard, Sawanyawisuth, Jitpimolmard (CR39) 2013; 35
Flowers, Veenstra (CR73) 2004; 22
Obradovic, Mrhar, Kos (CR43) 2008; 9
Saokaew, Tassaneeyakul, Maenthaisong, Chaiyakunapruk (CR35) 2014; 9
Lazarou, Pomeranz, Corey (CR3) 1998; 279
Verhoed, Redekop, Darba, Geitona, Hughes, Siebert (CR15) 2010; 11
Sorich, Horowitz, Sorich, Wiese, Pekarsky, Karnon (CR58) 2013; 14
You, Tsui, Wong, Cheng (CR51) 2012; 7
CR6
Olgiati, Bajo, Bigelli, Ronchi, Serretti (CR64) 2012; 36
Dubinsky, Reyes, Ofman, Chiou, Wade, Sandborn (CR25) 2005; 100
Mallal, Phillips, Carosi, Molina, Workman, Tomazic (CR9) 2008; 358
Sayani, Prosser, Bailey, Jacobs, Fedorak (CR30) 2005; 19
Pirmohamed (CR5) 2014; 15
Reese, Mullins, Beitelshees, Onukwugha (CR57) 2012; 32
Panattoni, Brown, Te Ao, Webster, Gladding (CR56) 2012; 30
Schackman, Scott, Walensky, Losina, Freedberg, Sax (CR11) 2008; 22
Gold, Hall, Blinder, Schackman (CR41) 2009; 115
Payne, Shabaruddin (CR72) 2010; 11
Beaulieu, de Denus, Lachaine (CR14) 2010; 11
Creinin, Lisman, Strickler (CR62) 1999; 72
Wong, Carlson, Thariani, Veenstra (CR71) 2010; 28
Ingelman-Sundberg (CR4) 2004; 25
Kimmel, French, Kasner, Johnson, Anderson, Gage (CR68) 2013; 369
Husereau, Drummond, Petrou (CR19) 2013; 16
van den Akker-van Marle (CR33) 2006; 7
Veenstra, Harris, Gibson, Rosenfeld, Burke, Watts (CR59) 2007; 9
Cargnin, Jommi, Canonico, Genazzani, Terrazzino (CR8) 2014; 15
Hughes, Vilar, Ward, Alfirevic, Park, Pirohamed (CR10) 2004; 14
You, Tsui, Wong, Cheng (CR47) 2009; 86
CR17
Leey, McCabe, Koch, Miles (CR45) 2009; 7
Davies, Green, Taylor, Williamson, Mottram, Pirmohamed (CR1) 2009; 4
Chantratita, Chantarangsu, Kiertiburanakul, Sungkanuparph, Charoenyingwattana, Mahasirimongkol (CR65) 2011; S6
Marra, Esdaile, Anis (CR27) 2002; 29
Priest, Begg, Gardiner, Frampton, Gearry, Barclay (CR29) 2006; 24
Pichereau, Louarn, Lecomte, Blasco, Guellec, Bourgoin (CR42) 2010; 13
Compagni, Bartoli, Buehrlen, Fattore, Ibarreta, de Mesa (CR16) 2008; 24
Moher, Liberati, Tetzlaff (CR18) 2009; 339
Wolf, Blankenburg, Bogner, Becker, Gorriahn, Mueller (CR21) 2010; 15
Park, Kang, Lee, Lee, Wen, Kim (CR36) 2015; 67
Plumpton, Yip, Alfirevic, Marson, Pirmohamed, Hughes (CR40) 2015; 56
Winter, Walker, Shapiro, Gaffney, Spooner, Mills (CR34) 2004; 20
Newman, Payne, Tricker, Roberts, Fargher, Pushpakom (CR67) 2011; 12
Smith, Monsef, Ragni (CR63) 2008; 100
Kauf, Farkouh, Earnshaw, Watson, Maroudas, Chambers (CR20) 2010; 28
Donnan, Ungar, Mathews, Hancock-Howard, Rahman (CR24) 2011; 57
Mallal, Phillips, Carosi, Molina, Workman, Tomazic (CR66) 2008; 358
Pirmohamed, Burnside, Eriksson, Jorgensen, Toh, Nicholson (CR69) 2013; 369
Eckman, Rosand, Greenberg, Gage (CR44) 2009; 150
Roberts, Wells, Le May, Labinaz, Glover, Froeschl (CR70) 2012; 379
Pink, Pirmohamed, Lane, Hughes (CR48) 2014; 95
Schalekamp, Boink, Visser, Stricker, de Boer, Klungel (CR50) 2006; 79
Oh, Anis, Bae (CR28) 2004; 43
Pirmohamed, James, Meakin, Green, Scott, Walley (CR2) 2004; 329
Tavadia, Mydlarski, Reis, Mittmann, Pinkerton, Shear (CR31) 2000; 42
TI Verhoef (397_CR54) 2013; 14
SK Kim (397_CR61) 2006; 33
TI Verhoed (397_CR15) 2010; 11
D Moher (397_CR18) 2009; 339
JD Roberts (397_CR70) 2012; 379
M Pirmohamed (397_CR5) 2014; 15
W Wolf (397_CR21) 2010; 15
CA Marra (397_CR27) 2002; 29
FA Sayani (397_CR30) 2005; 19
ES Reese (397_CR57) 2012; 32
D Dong (397_CR37) 2012; 79
S Saokaew (397_CR35) 2014; 9
A Lala (397_CR55) 2013; 11
MJ Sorich (397_CR58) 2013; 14
A Compagni (397_CR16) 2008; 24
WB Wong (397_CR71) 2010; 28
AR Patrick (397_CR46) 2009; 2
S Mallal (397_CR9) 2008; 358
397_CR17
P Olgiati (397_CR64) 2012; 36
JHS You (397_CR51) 2012; 7
S Pichereau (397_CR42) 2010; 13
ME Akker-van Marle van den (397_CR33) 2006; 7
KA Phillips (397_CR13) 2004; 5
MD Creinin (397_CR62) 1999; 72
J Lazarou (397_CR3) 1998; 279
M Pirmohamed (397_CR2) 2004; 329
397_CR6
JH You (397_CR47) 2009; 86
SM Tavadia (397_CR31) 2000; 42
M Beaulieu (397_CR14) 2010; 11
EC Davies (397_CR1) 2009; 4
DN Calatravaa (397_CR22) 2010; 28
F Dionne (397_CR60) 2012; 12
KT Oh (397_CR28) 2004; 43
A McWilliam (397_CR49) 2008; 5
KJ Smith (397_CR63) 2008; 100
MC Dubinsky (397_CR25) 2005; 100
K Payne (397_CR72) 2010; 11
CO Plumpton (397_CR40) 2015; 56
LM Meckley (397_CR52) 2010; 28
VL Priest (397_CR29) 2006; 24
W Chantratita (397_CR65) 2011; S6
BR Schackman (397_CR11) 2008; 22
DJ Park (397_CR36) 2015; 67
AJ Thompson (397_CR32) 2014; 17
CR Flowers (397_CR73) 2004; 22
S Tiamkao (397_CR39) 2013; 35
D Husereau (397_CR19) 2013; 16
S Mallal (397_CR66) 2008; 358
W Rattanavipapong (397_CR38) 2013; 54
MH Eckman (397_CR44) 2009; 150
S Cargnin (397_CR8) 2014; 15
DA Hughes (397_CR10) 2004; 14
DL Veenstra (397_CR59) 2007; 9
M Pirmohamed (397_CR12) 2013; 12
M Pirmohamed (397_CR69) 2013; 369
VL Yip (397_CR7) 2015; 48
HT Gold (397_CR41) 2009; 115
J Winter (397_CR34) 2004; 20
WG Newman (397_CR67) 2011; 12
J Pink (397_CR48) 2014; 95
TL Kauf (397_CR20) 2010; 28
JA Leey (397_CR45) 2009; 7
M Ingelman-Sundberg (397_CR4) 2004; 25
R Kapoor (397_CR23) 2015; 25
JR Donnan (397_CR24) 2011; 57
T Schalekamp (397_CR50) 2006; 79
SE Kimmel (397_CR68) 2013; 369
M Obradovic (397_CR43) 2008; 9
JH You (397_CR53) 2004; 92
JT Hagaman (397_CR26) 2010; 188
L Panattoni (397_CR56) 2012; 30
References_xml – volume: 339
  start-page: b2535
  year: 2009
  ident: CR18
  article-title: Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: BMJ
  doi: 10.1136/bmj.b2535
– volume: 22
  start-page: 481
  issue: 8
  year: 2004
  end-page: 493
  ident: CR73
  article-title: The role of cost-effectiveness analysis in the era of pharmacogenomics
  publication-title: Pharmacoeconomics
  doi: 10.2165/00019053-200422080-00001
– volume: 115
  start-page: 3858
  issue: 17
  year: 2009
  end-page: 3867
  ident: CR41
  article-title: Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer
  publication-title: Cancer
  doi: 10.1002/cncr.24428
– volume: 25
  start-page: 60
  year: 2015
  end-page: 72
  ident: CR23
  article-title: Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000107
– volume: 14
  start-page: 2013
  issue: 16
  year: 2013
  end-page: 2021
  ident: CR58
  article-title: Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.13.164
– volume: 379
  start-page: 1705
  issue: 9827
  year: 2012
  end-page: 1711
  ident: CR70
  article-title: Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60161-5
– volume: 15
  start-page: 145
  issue: 4
  year: 2010
  end-page: 151
  ident: CR21
  article-title: Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
  publication-title: Eur J Med Res
  doi: 10.1186/2047-783X-15-4-145
– volume: 9
  start-page: 539
  issue: 5
  year: 2008
  end-page: 549
  ident: CR43
  article-title: Cost–effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.9.5.539
– volume: 86
  start-page: 540
  issue: 5
  year: 2009
  end-page: 547
  ident: CR47
  article-title: Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2009.104
– volume: 100
  start-page: 2239
  issue: 10
  year: 2005
  end-page: 2247
  ident: CR25
  article-title: A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2005.41900.x
– volume: 358
  start-page: 568
  issue: 6
  year: 2008
  end-page: 579
  ident: CR66
  article-title: HLA-B*5701 screening for hypersensitivity to abacavir
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0706135
– volume: 11
  start-page: 81
  issue: 1
  year: 2013
  end-page: 91
  ident: CR55
  article-title: Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.12059
– volume: 329
  start-page: 15
  year: 2004
  end-page: 19
  ident: CR2
  article-title: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
  publication-title: BMJ
  doi: 10.1136/bmj.329.7456.15
– volume: 12
  start-page: 3
  year: 2013
  end-page: 4
  ident: CR12
  article-title: Pharmacogenetic tests: the need for a level playing field
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd3921
– volume: 36
  start-page: 147
  issue: 1
  year: 2012
  end-page: 154
  ident: CR64
  article-title: Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2011.08.013
– volume: 28
  start-page: 61
  issue: 1
  year: 2010
  end-page: 74
  ident: CR52
  article-title: A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing
  publication-title: Pharmacoeconomics
  doi: 10.2165/11318240-000000000-00000
– volume: 14
  start-page: 869
  issue: 8
  year: 2013
  end-page: 883
  ident: CR54
  article-title: Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.13.74
– volume: 28
  start-page: 1025
  issue: 11
  year: 2010
  end-page: 1038
  ident: CR20
  article-title: Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV
  publication-title: Pharmacoeconomics
  doi: 10.2165/11535540-000000000-00000
– volume: 9
  start-page: 695
  issue: 10
  year: 2007
  end-page: 704
  ident: CR59
  article-title: Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes
  publication-title: Genet Med
  doi: 10.1097/GIM.0b013e318156dd07
– volume: 7
  start-page: e39640
  issue: 6
  year: 2012
  ident: CR51
  article-title: Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation
  publication-title: PLoS One.
  doi: 10.1371/journal.pone.0039640
– volume: 369
  start-page: 2283
  issue: 24
  year: 2013
  end-page: 2293
  ident: CR68
  article-title: A pharmacogenetic versus a clinical algorithm for warfarin dosing
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1310669
– volume: 29
  start-page: 2507
  issue: 12
  year: 2002
  end-page: 2512
  ident: CR27
  article-title: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine
  publication-title: J Rheumatol
– volume: 92
  start-page: 590
  issue: 3
  year: 2004
  end-page: 597
  ident: CR53
  article-title: The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy: a decision analysis
  publication-title: Thromb Haemost
– volume: 15
  start-page: 349
  year: 2014
  end-page: 370
  ident: CR5
  article-title: Personalized pharmacogenomics: predicting efficacy and adverse drug reactions
  publication-title: Annu Rev Genomics Hum Genet
  doi: 10.1146/annurev-genom-090413-025419
– volume: 57
  start-page: 231
  issue: 2
  year: 2011
  end-page: 239
  ident: CR24
  article-title: A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.22936
– volume: 9
  start-page: e94294
  issue: 4
  year: 2014
  ident: CR35
  article-title: Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0094294
– volume: 79
  start-page: 511
  issue: 6
  year: 2006
  end-page: 520
  ident: CR50
  article-title: CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2006.03.008
– volume: 28
  start-page: 590
  issue: 9
  year: 2010
  end-page: 595
  ident: CR22
  article-title: Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV + patients in Spain
  publication-title: Enferm Infecc Microbiol Clin
  doi: 10.1016/j.eimc.2009.09.010
– volume: 43
  start-page: 156
  issue: 2
  year: 2004
  end-page: 163
  ident: CR28
  article-title: Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keh001
– volume: 95
  start-page: 199
  issue: 2
  year: 2014
  end-page: 207
  ident: CR48
  article-title: Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2013.190
– volume: 11
  start-page: 643
  issue: 5
  year: 2010
  end-page: 646
  ident: CR72
  article-title: Cost-effectiveness analysis in pharmacogenomics
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.10.45
– volume: 20
  start-page: 593
  issue: 6
  year: 2004
  end-page: 599
  ident: CR34
  article-title: Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2004.02124.x
– volume: 25
  start-page: 193
  year: 2004
  end-page: 200
  ident: CR4
  article-title: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2004.02.007
– volume: 48
  start-page: 165
  issue: 2–3
  year: 2015
  end-page: 175
  ident: CR7
  article-title: Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review
  publication-title: Clin Rev Allergy Immunol
  doi: 10.1007/s12016-014-8418-y
– volume: 11
  start-page: 989
  issue: 7
  year: 2010
  end-page: 1002
  ident: CR15
  article-title: A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.10.74
– volume: 2
  start-page: 429
  issue: 5
  year: 2009
  end-page: 436
  ident: CR46
  article-title: Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation
  publication-title: Circ Cardiovasc Qual Outcomes
  doi: 10.1161/CIRCOUTCOMES.108.808592
– volume: 22
  start-page: 2025
  year: 2008
  end-page: 2033
  ident: CR11
  article-title: The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e3283103ce6
– volume: 30
  start-page: 1067
  issue: 11
  year: 2012
  end-page: 1084
  ident: CR56
  article-title: The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation
  publication-title: Pharmacoeconomics
  doi: 10.2165/11595080-000000000-00000
– volume: 28
  start-page: 1001
  issue: 11
  year: 2010
  end-page: 1013
  ident: CR71
  article-title: Cost effectiveness of pharmacogenomics: a critical and systematic review
  publication-title: Pharmacoeconomics
  doi: 10.2165/11537410-000000000-00000
– volume: 24
  start-page: 294
  issue: 3
  year: 2008
  end-page: 302
  ident: CR16
  article-title: Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects
  publication-title: Int J Technol Assess Health Care
  doi: 10.1017/S0266462308080392
– volume: 19
  start-page: 147
  issue: 3
  year: 2005
  end-page: 151
  ident: CR30
  article-title: Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events
  publication-title: Can J Gastroenterol
  doi: 10.1155/2005/470863
– volume: 12
  start-page: 815
  issue: 6
  year: 2011
  end-page: 826
  ident: CR67
  article-title: A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.11.32
– volume: 15
  start-page: 963
  issue: 7
  year: 2014
  end-page: 976
  ident: CR8
  article-title: Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.14.52
– volume: 4
  start-page: e4439
  year: 2009
  ident: CR1
  article-title: Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0004439
– volume: 32
  start-page: 323
  issue: 4
  year: 2012
  end-page: 332
  ident: CR57
  article-title: Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel
  publication-title: Pharmacotherapy
  doi: 10.1002/j.1875-9114.2012.01048
– volume: 279
  start-page: 1200
  year: 1998
  end-page: 1205
  ident: CR3
  article-title: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies
  publication-title: JAMA
  doi: 10.1001/jama.279.15.1200
– volume: 12
  start-page: 205
  issue: 3
  year: 2012
  end-page: 213
  ident: CR60
  article-title: Economic impact of a genetic test for cisplatin-induced ototoxicity
  publication-title: Pharmacogenomics J
  doi: 10.1038/tpj.2011.15
– ident: CR6
– volume: 100
  start-page: 447
  issue: 3
  year: 2008
  end-page: 452
  ident: CR63
  article-title: Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis
  publication-title: Thromb Haemost
– volume: 7
  start-page: 783
  issue: 5
  year: 2006
  end-page: 792
  ident: CR33
  article-title: Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, de Mesa E, Ibarreta DG. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.7.5.783
– volume: 33
  start-page: 1266
  issue: 7
  year: 2006
  end-page: 1274
  ident: CR61
  article-title: Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate
  publication-title: J Rheumatol
– volume: 42
  start-page: 628
  issue: 4
  year: 2000
  end-page: 632
  ident: CR31
  article-title: Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case
  publication-title: J Am Acad Dermatol
  doi: 10.1067/mjd.2000.103980
– volume: 72
  start-page: 646
  issue: 4
  year: 1999
  end-page: 651
  ident: CR62
  article-title: Screening for factor V Leiden mutation before prescribing combination oral contraceptives
  publication-title: Fertil Steril
  doi: 10.1016/S0015-0282(99)00318-0
– volume: 79
  start-page: 1259
  issue: 12
  year: 2012
  end-page: 1267
  ident: CR37
  article-title: Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31826aac73
– volume: 56
  start-page: 556
  issue: 4
  year: 2015
  end-page: 563
  ident: CR40
  article-title: Cost effectiveness of screening for HLA-A*31:01 prior to initiation of Carbamazepine in epilepsy
  publication-title: Epilepsia.
  doi: 10.1111/epi.12937
– volume: 24
  start-page: 767
  issue: 8
  year: 2006
  end-page: 781
  ident: CR29
  article-title: Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease
  publication-title: Pharmacoeconomics
  doi: 10.2165/00019053-200624080-00004
– volume: 17
  start-page: 22
  issue: 1
  year: 2014
  end-page: 33
  ident: CR32
  article-title: The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine
  publication-title: Value Health
  doi: 10.1016/j.jval.2013.10.007
– volume: 358
  start-page: 568
  year: 2008
  end-page: 579
  ident: CR9
  article-title: HLA-B*5701 screening for hypersensitivity reaction
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0706135
– volume: 35
  start-page: 608
  issue: 4
  year: 2013
  end-page: 612
  ident: CR39
  article-title: Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand
  publication-title: Int J Clin Pharm
  doi: 10.1007/s11096-013-9777-9
– volume: 5
  start-page: 1139
  issue: 8
  year: 2004
  end-page: 1149
  ident: CR13
  article-title: A systematic review of cost-effectiveness analyses of pharmacogenomic interventions
  publication-title: Pharmacogenomics
  doi: 10.1517/14622416.5.8.1139
– volume: 16
  start-page: 231
  year: 2013
  end-page: 250
  ident: CR19
  article-title: ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
  publication-title: Value Health.
  doi: 10.1016/j.jval.2013.02.002
– volume: 14
  start-page: 335
  year: 2004
  end-page: 342
  ident: CR10
  article-title: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200406000-00002
– volume: 11
  start-page: 1573
  issue: 11
  year: 2010
  end-page: 1590
  ident: CR14
  article-title: Systematic review of pharmacoeconomic studies of pharmacogenomic tests
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.10.145
– ident: CR17
– volume: 150
  start-page: 73
  issue: 2
  year: 2009
  end-page: 83
  ident: CR44
  article-title: Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-150-2-200901200-00005
– volume: 188
  start-page: 125
  issue: 2
  year: 2010
  end-page: 132
  ident: CR26
  article-title: Thiopurine S-methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis
  publication-title: Lung
  doi: 10.1007/s00408-009-9217-8
– volume: 5
  start-page: 279
  issue: 3
  year: 2008
  end-page: 284
  ident: CR49
  article-title: Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin
  publication-title: Per Med
  doi: 10.2217/17410541.5.3.279
– volume: 13
  start-page: 615
  issue: 4
  year: 2010
  end-page: 625
  ident: CR42
  article-title: Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer
  publication-title: J Pharm Pharm Sci
  doi: 10.18433/J3WK5S
– volume: 67
  start-page: 280
  issue: 2
  year: 2015
  end-page: 287
  ident: CR36
  article-title: Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.22409
– volume: 54
  start-page: 1628
  issue: 9
  year: 2013
  end-page: 1638
  ident: CR38
  article-title: Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand
  publication-title: Epilepsia
  doi: 10.1111/epi.12325
– volume: S6
  start-page: 001
  year: 2011
  ident: CR65
  article-title: Integrating HIV-1 Pharmacogenomics into the Universal Coverage Health-Care System in Thailand: from scientific evidence to policy
  publication-title: J Pharmacogenom Pharmacoproteomics
– volume: 369
  start-page: 2294
  issue: 24
  year: 2013
  end-page: 2303
  ident: CR69
  article-title: A randomized trial of genotype-guided dosing of warfarin
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1311386
– volume: 7
  start-page: 197
  issue: 4
  year: 2009
  end-page: 203
  ident: CR45
  article-title: Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation
  publication-title: Am J Geriatr Pharmacother
  doi: 10.1016/j.amjopharm.2009.07.002
– volume: 15
  start-page: 145
  issue: 4
  year: 2010
  ident: 397_CR21
  publication-title: Eur J Med Res
  doi: 10.1186/2047-783X-15-4-145
– volume: 188
  start-page: 125
  issue: 2
  year: 2010
  ident: 397_CR26
  publication-title: Lung
  doi: 10.1007/s00408-009-9217-8
– volume: 7
  start-page: e39640
  issue: 6
  year: 2012
  ident: 397_CR51
  publication-title: PLoS One.
  doi: 10.1371/journal.pone.0039640
– volume: 28
  start-page: 1025
  issue: 11
  year: 2010
  ident: 397_CR20
  publication-title: Pharmacoeconomics
  doi: 10.2165/11535540-000000000-00000
– volume: 11
  start-page: 989
  issue: 7
  year: 2010
  ident: 397_CR15
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.10.74
– volume: 379
  start-page: 1705
  issue: 9827
  year: 2012
  ident: 397_CR70
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60161-5
– volume: 100
  start-page: 2239
  issue: 10
  year: 2005
  ident: 397_CR25
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2005.41900.x
– volume: 29
  start-page: 2507
  issue: 12
  year: 2002
  ident: 397_CR27
  publication-title: J Rheumatol
– volume: 24
  start-page: 294
  issue: 3
  year: 2008
  ident: 397_CR16
  publication-title: Int J Technol Assess Health Care
  doi: 10.1017/S0266462308080392
– volume: 28
  start-page: 1001
  issue: 11
  year: 2010
  ident: 397_CR71
  publication-title: Pharmacoeconomics
  doi: 10.2165/11537410-000000000-00000
– volume: 14
  start-page: 869
  issue: 8
  year: 2013
  ident: 397_CR54
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.13.74
– volume: 95
  start-page: 199
  issue: 2
  year: 2014
  ident: 397_CR48
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2013.190
– volume: 28
  start-page: 590
  issue: 9
  year: 2010
  ident: 397_CR22
  publication-title: Enferm Infecc Microbiol Clin
  doi: 10.1016/j.eimc.2009.09.010
– volume: 12
  start-page: 815
  issue: 6
  year: 2011
  ident: 397_CR67
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.11.32
– volume: 57
  start-page: 231
  issue: 2
  year: 2011
  ident: 397_CR24
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.22936
– volume: 4
  start-page: e4439
  year: 2009
  ident: 397_CR1
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0004439
– volume: 25
  start-page: 193
  year: 2004
  ident: 397_CR4
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2004.02.007
– volume: 14
  start-page: 2013
  issue: 16
  year: 2013
  ident: 397_CR58
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.13.164
– volume: 369
  start-page: 2283
  issue: 24
  year: 2013
  ident: 397_CR68
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1310669
– volume: 15
  start-page: 963
  issue: 7
  year: 2014
  ident: 397_CR8
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.14.52
– volume: 22
  start-page: 2025
  year: 2008
  ident: 397_CR11
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e3283103ce6
– volume: 115
  start-page: 3858
  issue: 17
  year: 2009
  ident: 397_CR41
  publication-title: Cancer
  doi: 10.1002/cncr.24428
– volume: 5
  start-page: 279
  issue: 3
  year: 2008
  ident: 397_CR49
  publication-title: Per Med
  doi: 10.2217/17410541.5.3.279
– volume: 36
  start-page: 147
  issue: 1
  year: 2012
  ident: 397_CR64
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2011.08.013
– volume: 12
  start-page: 205
  issue: 3
  year: 2012
  ident: 397_CR60
  publication-title: Pharmacogenomics J
  doi: 10.1038/tpj.2011.15
– volume: 72
  start-page: 646
  issue: 4
  year: 1999
  ident: 397_CR62
  publication-title: Fertil Steril
  doi: 10.1016/S0015-0282(99)00318-0
– volume: 12
  start-page: 3
  year: 2013
  ident: 397_CR12
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd3921
– volume: 11
  start-page: 81
  issue: 1
  year: 2013
  ident: 397_CR55
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.12059
– volume: 33
  start-page: 1266
  issue: 7
  year: 2006
  ident: 397_CR61
  publication-title: J Rheumatol
– volume: 22
  start-page: 481
  issue: 8
  year: 2004
  ident: 397_CR73
  publication-title: Pharmacoeconomics
  doi: 10.2165/00019053-200422080-00001
– volume: 15
  start-page: 349
  year: 2014
  ident: 397_CR5
  publication-title: Annu Rev Genomics Hum Genet
  doi: 10.1146/annurev-genom-090413-025419
– volume: 329
  start-page: 15
  year: 2004
  ident: 397_CR2
  publication-title: BMJ
  doi: 10.1136/bmj.329.7456.15
– volume: 42
  start-page: 628
  issue: 4
  year: 2000
  ident: 397_CR31
  publication-title: J Am Acad Dermatol
  doi: 10.1067/mjd.2000.103980
– volume: 5
  start-page: 1139
  issue: 8
  year: 2004
  ident: 397_CR13
  publication-title: Pharmacogenomics
  doi: 10.1517/14622416.5.8.1139
– volume: 86
  start-page: 540
  issue: 5
  year: 2009
  ident: 397_CR47
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2009.104
– volume: 9
  start-page: 539
  issue: 5
  year: 2008
  ident: 397_CR43
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.9.5.539
– volume: 79
  start-page: 1259
  issue: 12
  year: 2012
  ident: 397_CR37
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31826aac73
– volume: 7
  start-page: 783
  issue: 5
  year: 2006
  ident: 397_CR33
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.7.5.783
– volume: 56
  start-page: 556
  issue: 4
  year: 2015
  ident: 397_CR40
  publication-title: Epilepsia.
  doi: 10.1111/epi.12937
– volume: 32
  start-page: 323
  issue: 4
  year: 2012
  ident: 397_CR57
  publication-title: Pharmacotherapy
  doi: 10.1002/j.1875-9114.2012.01048
– volume: 13
  start-page: 615
  issue: 4
  year: 2010
  ident: 397_CR42
  publication-title: J Pharm Pharm Sci
  doi: 10.18433/J3WK5S
– volume: 358
  start-page: 568
  issue: 6
  year: 2008
  ident: 397_CR66
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0706135
– volume: 358
  start-page: 568
  year: 2008
  ident: 397_CR9
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0706135
– volume: 30
  start-page: 1067
  issue: 11
  year: 2012
  ident: 397_CR56
  publication-title: Pharmacoeconomics
  doi: 10.2165/11595080-000000000-00000
– volume: 17
  start-page: 22
  issue: 1
  year: 2014
  ident: 397_CR32
  publication-title: Value Health
  doi: 10.1016/j.jval.2013.10.007
– volume: 7
  start-page: 197
  issue: 4
  year: 2009
  ident: 397_CR45
  publication-title: Am J Geriatr Pharmacother
  doi: 10.1016/j.amjopharm.2009.07.002
– volume: 25
  start-page: 60
  year: 2015
  ident: 397_CR23
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000107
– volume: 9
  start-page: e94294
  issue: 4
  year: 2014
  ident: 397_CR35
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0094294
– volume: 369
  start-page: 2294
  issue: 24
  year: 2013
  ident: 397_CR69
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1311386
– volume: 9
  start-page: 695
  issue: 10
  year: 2007
  ident: 397_CR59
  publication-title: Genet Med
  doi: 10.1097/GIM.0b013e318156dd07
– volume: 14
  start-page: 335
  year: 2004
  ident: 397_CR10
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200406000-00002
– volume: 67
  start-page: 280
  issue: 2
  year: 2015
  ident: 397_CR36
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.22409
– volume: 20
  start-page: 593
  issue: 6
  year: 2004
  ident: 397_CR34
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2004.02124.x
– ident: 397_CR6
– volume: 35
  start-page: 608
  issue: 4
  year: 2013
  ident: 397_CR39
  publication-title: Int J Clin Pharm
  doi: 10.1007/s11096-013-9777-9
– volume: 79
  start-page: 511
  issue: 6
  year: 2006
  ident: 397_CR50
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2006.03.008
– volume: 100
  start-page: 447
  issue: 3
  year: 2008
  ident: 397_CR63
  publication-title: Thromb Haemost
  doi: 10.1160/TH08-03-0149
– volume: 54
  start-page: 1628
  issue: 9
  year: 2013
  ident: 397_CR38
  publication-title: Epilepsia
  doi: 10.1111/epi.12325
– volume: S6
  start-page: 001
  year: 2011
  ident: 397_CR65
  publication-title: J Pharmacogenom Pharmacoproteomics
– volume: 11
  start-page: 643
  issue: 5
  year: 2010
  ident: 397_CR72
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.10.45
– volume: 43
  start-page: 156
  issue: 2
  year: 2004
  ident: 397_CR28
  publication-title: Rheumatology
– volume: 48
  start-page: 165
  issue: 2–3
  year: 2015
  ident: 397_CR7
  publication-title: Clin Rev Allergy Immunol
  doi: 10.1007/s12016-014-8418-y
– volume: 339
  start-page: b2535
  year: 2009
  ident: 397_CR18
  publication-title: BMJ
  doi: 10.1136/bmj.b2535
– volume: 16
  start-page: 231
  year: 2013
  ident: 397_CR19
  publication-title: Value Health.
  doi: 10.1016/j.jval.2013.02.002
– volume: 279
  start-page: 1200
  year: 1998
  ident: 397_CR3
  publication-title: JAMA
  doi: 10.1001/jama.279.15.1200
– volume: 150
  start-page: 73
  issue: 2
  year: 2009
  ident: 397_CR44
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-150-2-200901200-00005
– volume: 92
  start-page: 590
  issue: 3
  year: 2004
  ident: 397_CR53
  publication-title: Thromb Haemost
– volume: 2
  start-page: 429
  issue: 5
  year: 2009
  ident: 397_CR46
  publication-title: Circ Cardiovasc Qual Outcomes
  doi: 10.1161/CIRCOUTCOMES.108.808592
– ident: 397_CR17
– volume: 24
  start-page: 767
  issue: 8
  year: 2006
  ident: 397_CR29
  publication-title: Pharmacoeconomics
  doi: 10.2165/00019053-200624080-00004
– volume: 28
  start-page: 61
  issue: 1
  year: 2010
  ident: 397_CR52
  publication-title: Pharmacoeconomics
  doi: 10.2165/11318240-000000000-00000
– volume: 11
  start-page: 1573
  issue: 11
  year: 2010
  ident: 397_CR14
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.10.145
– volume: 19
  start-page: 147
  issue: 3
  year: 2005
  ident: 397_CR30
  publication-title: Can J Gastroenterol
  doi: 10.1155/2005/470863
SSID ssj0006372
Score 2.481942
SecondaryResourceType review_article
Snippet Background Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines....
Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine...
Background Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines....
BACKGROUNDPharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines....
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 771
SubjectTerms Adverse and side effects
Cost-Benefit Analysis
Drug-Related Side Effects and Adverse Reactions - economics
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - prevention & control
Drugs
Economic aspects
Evaluation
Genotype
Health Administration
Health Economics
Humans
Incidence
Medicine
Medicine & Public Health
Methods
Pharmacoeconomics and Health Outcomes
Pharmacogenetics
Pharmacogenetics - economics
Pharmacogenetics - methods
Pharmacogenomic Testing - economics
Pharmacogenomic Testing - methods
Public Health
Quality of Life Research
Side effects
Systematic Review
SummonAdditionalLinks – databaseName: SpringerLINK Contemporary 1997-Present
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-2bqyFso-sH1m7ocHooKtBsWRbfgxdyx62Etas9M3IslwKxS5xUuh_3zvZcpuyDbbX-HxR0E-6u9zd7wA-5UJHOTcqSNBcBxKNQKBGWgShjDF4zjU3rprw7HtycqLOz9NJ18fd-Gp3n5J0N3Xf7CaJegVDX4yA0YgG6VN4htZO0byGn6dn_fUbCzexyU1USTD286nM36lYMkaPr-QHNulRktTZnuNX_7Xq1_CyczXZuMXGG3hiqwGs-k7kZgAvfnSJ9QHsTVoK69sDNr3vyGoO2B6b3JNb3w5gvf2fj7XtS2-hHrPTngyatZkGVpfMfw076unEG_rca0PcUvskmxLLR3XB0Hdmnk6qrkjSjYpuLPs6W1yg4rYBo9mAX8dH08NvQTfEITDo68wDIbkyohS8jEpTontUGPSIYmlMjiiROuZSh1bjvpVWcstDncg8sjoWo5ibIhKbsFLVld0GlqhCa6UNujglokrpskBVRRqheqF1MQTudzMzHcM5Ddq4ynpuZrcbGVW10W5k6RD2-1euW3qPvwl_JohkdPRRr9FdBwOujki0snEykkR3H_Eh7C5J4pE1y489yLLuymgyDPTQFYtlOhrCx_4xvUllcJWtFySDEW2YJApltlpw9ssO41TJKETlXzwSHyj_029690_SO7AWOihTAeQurMxnC_senpub-WUz--DO4R1v0Cmy
  priority: 102
  providerName: Springer Nature
Title A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions
URI https://link.springer.com/article/10.1007/s40273-016-0397-9
https://www.ncbi.nlm.nih.gov/pubmed/26984520
https://www.proquest.com/docview/1821106491
https://www.proquest.com/docview/1801427781
Volume 34
WOSCitedRecordID wos000379175100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: ABI/INFORM Global
  customDbUrl:
  eissn: 1179-2027
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0006372
  issn: 1170-7690
  databaseCode: M0C
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/abiglobal
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1179-2027
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0006372
  issn: 1170-7690
  databaseCode: 7X7
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Healthcare Administration Database
  customDbUrl:
  eissn: 1179-2027
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0006372
  issn: 1170-7690
  databaseCode: M0T
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthmanagement
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest ABI/INFORM Collection
  customDbUrl:
  eissn: 1179-2027
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0006372
  issn: 1170-7690
  databaseCode: 7WY
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/abicomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1179-2027
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0006372
  issn: 1170-7690
  databaseCode: BENPR
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Psychology Database
  customDbUrl:
  eissn: 1179-2027
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0006372
  issn: 1170-7690
  databaseCode: M2M
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/psychology
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 1179-2027
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0006372
  issn: 1170-7690
  databaseCode: 8C1
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1179-2027
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0006372
  issn: 1170-7690
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-xDQleYIyvwlYZCQ0JFuEkTuw8TV3pxAOrqq2M7ilynGSaNCWjaZH233PnfHSdxF54uYfkfHLk8905vvsdwMfE10HCjXIkumtHoBNwlKt9xxMhHp4TzY3NJjz_IcdjNZtFk-aHW9WkVbY20RrqtDT0j_wrxsHoqUIRuYc3vx3qGkW3q00LjQ3YosiGUvpO-LCzxKFvmzfZ5ioSj4HtrSaVzgkCcsGDNJ6n0SU70Zpfum-d77ine_el1g0dP__fD9iGZ00Ayga1xryAR1mxA0_a-uRqB_YnNZr17QGbroqzqgO2zyYrnOvbl1AO2FmHA83qSwZW5qyVxUYdknhFz9vRqLJUOcmmBPBRXDIMm1mLJFUWxGm7RFcZ-zZfXqLguvaiegU_j0fT4Xen6d_gGAxzFo4vuDJ-7vM8yE2OkVFqMBgKhTEJKojQIRfayzSuU54JnnFPS5EEmQ59N-QmDfzXsFmURfYWmFSp1kobjG5yVCil8xRFpVGA4n2t0x7wdvVi04CbU4-N67iDZbYLHlNCGy14HPXgczfkpkb2eIj5E6lETLse5RrdFC_g7Ag_Kx5IVxDSfcB7sLvGibvVrL9utSNurEUVr1SjBx-61zSSMuCKrFwSDx5mPSkV8ryplbGbthdGSgQeCv_Saucd4f_6pncPT-U9PPXs9qBkx13YXMyX2R48Nn8WV9W8Dxvy1wXRmbRUIVVDtw9bR6Px5LRvN6KlU6LeCdLTs_O_Gtkz_g
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB5VBalceJRXoMAiQZGgFht7ba8PCEV9qFVDFImAejPr9bqqVNklTkD5U_xGZtZep6lEbz1wjWdHG2dmvp3szDcAb7JAhRnX0osRrj2BIODJvgo8X0SYPGeKa1tN-H0Yj0by5CQZr8Ef1wtDZZUuJtpAnVea_iP_iOdgRKpIJP3PFz89mhpFt6tuhEZjFsdm8RtTtvrT0R7-vm99_2B_snvotVMFPI3gO_MCwaUOioAXYaELxOtcI0RHQusMty1UxIXyjUJrLIzghvsqFlloVBT0I65zmhKBIf-WEOgeVCrId7vIHwV2WJQd5hJj2uluUalVTxBxDCbumL_jEcBLVnDwKhpcgsMr97MW9g7u_W8v7D7cbQ_YbNB4xANYM-UmbLj-63oTtscNW_dih02WzWf1Dttm4yWP9-IhVAP2teO5Zs0lCqsK5nSx_Y4pvabP3Wp0SeoMZRMiMClPGaYFzDFlVSVJ2inYtWF70_kpKm56S-pH8O1GXsxjWC-r0jwFFstcKak0nt4KdBipihxV5UmI6gOl8h5wZy2pbsnbaYbIedrRTlsDS6lgjwwsTXrwvlty0TCXXCf8jkwwpaiGerVqmzNwd8QPlg7iviAm_5D3YGtFEqORXn3srDFto2GdLk2xB6-7x7SSKvxKU81JBpN1P44lyjxpjL_bth8lUoQ-Kv_gvOGS8n99p2fXb-UVbBxOvgzT4dHo-Dnc8a1rUmHnFqzPpnPzAm7rX7OzevrSOjmDHzftJH8B5RGJNQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED9NAwEvfIyvwgAjwZDGormOkzgPCFXrKqZNVSUK2ltwHGdCQsloWlD_Nf467pI4XSextz3wmtgnJ7m7ny---x3Am9TXQcqN8iKEa08iCHiqr31PyBCD51RzU2cTfj2JxmN1ehpPNuCPq4WhtErnE2tHnZWG_pHv4z4YkSqUcX8_b9MiJsPRx_OfHnWQopNW106jUZFju_yN4Vv14WiI3_qtEKPD6cEnr-0w4BkE4rnnS66Mn_s8D3KTI3ZnBuE6lMak-AhSh1xqYTVqZm4lt1zoSKaB1aHfD7nJqGMEuv8bkUTYpLRBftChQOjXjaPqxi4RhqDuRJXK9iSRyGAQj7E8bge8eA0TLyPDBWi8dFZbQ-Do3v_88u7D3XbjzQaNpTyADVtswW1Xl11twc6kYfFe7rHpqiit2mM7bLLi914-hHLAPnf816w5XGFlzpwsdtgxqFd03c1GU6WKUTYlYpPijGG4wByDVlnQyLo7dmXZcLY4Q8FNzUn1CL5cy4t5DJtFWdinwCKVaa20wV1djoakdJ6hqCwOULyvddYD7jQnMS2pO_UW-ZF0dNS1siWUyEfKlsQ92O2mnDeMJlcNfkfqmJC3Q7lGt0UbuDriDUsGUV8Sw3_Ae7C9NhK9lFm_7TQzab1klazUsgevu9s0kzL_ClsuaAwG8SKKFI550hhCt2wRxkoGAoW_d5ZxQfi_nunZ1Ut5BbfQNpKTo_Hxc7gjaiulfM9t2JzPFvYF3DS_5t-r2cva3hl8u24b-QvyW5H7
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Systematic+Review+of+Economic+Evaluations+of+Pharmacogenetic+Testing+for+Prevention+of+Adverse+Drug+Reactions&rft.jtitle=PharmacoEconomics&rft.au=Plumpton%2C+Catrin+O&rft.au=Roberts%2C+Daniel&rft.au=Pirmohamed%2C+Munir&rft.au=Hughes%2C+Dyfrig+A&rft.date=2016-08-01&rft.pub=Springer+Nature+B.V&rft.issn=1170-7690&rft.eissn=1179-2027&rft.volume=34&rft.issue=8&rft.spage=771&rft_id=info:doi/10.1007%2Fs40273-016-0397-9&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4187481201
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1170-7690&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1170-7690&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1170-7690&client=summon